Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
All >

Deals > A Fine Selection by [iito]

[ # 12 & 35 ]
Find below a fine selection of interesting & curious, important & meaningless deals by [iito] Business Intelligence
|

Total search results: 678 | Ordered by Date (descending)
1 2 3 4 5 6 7  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Delta 4–SEVERAL: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office 2021-04-07
Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA 2021-04-01
Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience 2021-03-30
Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare 2021-03-17
GenMark–Roche: investment, 202103– acquisition $1.8b recommended cash tender offer at $24.05/share premium of 43% 2021-03-15
Monte Rosa Therapeutics–SEVERAL: investment, 202103 financing round Series C $95m led by new investor Avoro Capital Advisors 2021-03-12
Relief Therapeutics–OTHER: investment, 202103 private placement CHF10m with 41.5m shares at CHF0.2412/share with institutional US investor 2021-03-12
AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group 2021-03-10
BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings 2021-03-09
Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen 2021-03-08
Bruker–Cowen: investor conference, 202103 supply service Bruker presents at Cowen & Co Annual Health Care Conference 2021 2021-03-02
Kairos GmbH–Iqvia: investment, 202103 acquisition of Kairos GmbH by Iqvia 2021-03-01
Silicon Therapeutics–Roivant: investment, 202102– acquisition $450m in shares + milestones by Roivant Sciences ANNOUNCED 2021-02-26
Bruker–SVB: investor conference, 202102 supply service Bruker presents at SVB Leerink Global Healthcare Conference 2021-02-25
Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc 2021-02-24
Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital 2021-02-24
Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares 2021-02-15
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
Genopis–Wacker: investment, 202102 acquisition of Genopis Inc for $39m in cash + milestones from Helixmith Co Ltd + Medivate Partners LLC 2021-02-03
Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test 2021-01-28
Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund 2021-01-28
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences 2021-01-26
Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB 2021-01-26
Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital 2021-01-25
CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share 2021-01-25
i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors 2021-01-25
TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital 2021-01-25
Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx 2021-01-21
Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq 2021-01-20
LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG 2021-01-18
IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments 2021-01-13
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share 2021-01-12
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI 2021-01-11
Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED 2021-01-11
Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners 2021-01-11
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP 2021-01-11
AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp 2021-01-06
Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic 2021-01-04
Biosun Biochemicals–BRAIN: investment, 202101 acquisition 100% €na by BRAIN AG 2021-01-01
Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use 2021-01-01
SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m 2020-12-22
Evotec–Alloy Therapeutics: transgenic mouse technolgy, 202012– supply access to ATX-Gx platform to expand Evotec antibody discovery platform 2020-12-21
Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital 2020-12-21
Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED 2020-12-17
MYR GmbH–Gilead Sciences: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc 2020-12-10
NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer 2020-12-10
Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services 2020-12-10
Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius 2020-12-09
Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets 2020-12-07
MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m 2020-12-01
Noema Pharma–SEVERAL: investment, 202012 financing round Series A CHF54m ($59m) co-led by Sofinnova Partners + Polaris Partners 2020-12-01
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM 2020-11-30
BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies 2020-11-25
Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF 2020-11-25
Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund 2020-11-25
Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio 2020-11-23
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic 2020-11-18
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties 2020-11-16
Start Codon–SEVERAL: investment, 202011 closing of Start Codon Fund I LP at £15m incl LPs Novartis International AG + Cambridge Innovation Capital 2020-11-16
m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences 2020-11-12
Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund 2020-11-12
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets 2020-11-11
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III 2020-11-10
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties 2020-11-09
Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB 2020-11-05
Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures 2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) 2020-11-02
Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing 2020-11-01
TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly 2020-10-27
AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones 2020-10-26
Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec 2020-10-26
MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs 2020-10-26
Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva 2020-10-20
ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group 2020-10-20
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors 2020-10-19
Azitra–SEVERAL: investment, 202010 financing round Series B $17m led by Leaps by Bayer 2020-10-15
VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors 2020-10-15
RayzeBio–SEVERAL: investment, 202010 financing round Series A $45m co-led by venBio Partners + Versant Ventures 2020-10-14
Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds 2020-10-13
Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink 2020-10-13
Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds 2020-10-13
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures 2020-10-07
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis 2020-10-06
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED 2020-10-02
Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures 2020-10-01
Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR 2020-10-01
Integrated Proteomics Applications–Bruker: investment, 202009 acquisition €na of assets by Bruker 2020-09-30
Dewpoint Therapeutics–SEVERAL: investment, 202009 financing round Series B $77m led by ARCH Venture Partners 2020-09-29
Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL 2020-09-28
XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside 2020-09-28
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures 2020-09-25
Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures 2020-09-25
Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital 2020-09-24
1 2 3 4 5 6 7  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

» top